VJHemOnc is committed to improving our service to you

ASH 2019 | Radiotherapy bridging for axi-cel in large B-cell lymphoma

VJHemOnc is committed to improving our service to you

Loretta Nastoupil

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the use of CAR-T therapy for large B-cell lymphoma. Dr Nastoupil focuses on bridging interventions prior to CAR-T therapy, since many patients have highly symptomatic, rapidly progressive disease that if left untreated during the 3-4 week manufacturing interval could be fatal. Preliminary data suggests that radiotherapy can be an effective bridging tool for relapsed/refractory (R/R) large B-cell lymphoma before axicabtagene ciloleucel (axi-cel) therapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter